Follicle centre lymphoma diffuse small cell lymphoma is a type of cancer that starts in specific white blood cells and primarily affects the skin. It falls under a broader category of cancers known as primary cutaneous B-cell lymphomas, which are relatively rare conditions that require careful diagnosis and monitoring over time.
Understanding the Disease
Primary cutaneous follicle center lymphoma, often referred to by its abbreviation PCFCL, is a cancer that develops from B cells, which are white blood cells that normally help fight infections. When these cells become cancerous, they form a type of lymphoma, which is a cancer affecting the lymphatic system. What makes this condition “primary cutaneous” is that it appears only in the skin at the time of diagnosis, without any evidence that the disease has spread to lymph nodes or other parts of the body.[1]
The lymphoma cells in PCFCL come from the center of lymph follicles, which are tiny structures found in lymph nodes where immune cells normally gather and multiply. These cancerous cells can grow in different patterns under the microscope. Some cases show a follicular pattern, where the cells cluster together in groups that look like normal follicles. Other cases show a diffuse pattern, where the cancer cells spread out more evenly throughout the skin tissue. Some patients have a mixed pattern with both follicular and diffuse areas.[1]
Among all primary cutaneous lymphomas affecting the skin, about 25 percent are B-cell lymphomas, while the remaining 75 to 80 percent are T-cell lymphomas. Within the B-cell category, PCFCL stands out as the most common type, accounting for more than half of all cutaneous B-cell lymphoma cases.[1][3]
Who Gets This Condition: Epidemiology
Primary cutaneous follicle center lymphoma is most frequently seen in Western countries, where it represents the most common form of B-cell lymphoma affecting the skin. The condition typically appears in middle-aged adults, with most patients being diagnosed when they are between 50 and 60 years old. The disease is extremely rare in children and young adults.[1][12]
There is a slight preference for the condition to affect men more than women. For every 1.5 men diagnosed with PCFCL, approximately one woman receives the same diagnosis. The disease is notably more common in people who are white compared to people of other racial backgrounds.[1][4]
Within the broader landscape of all cutaneous lymphomas, PCFCL accounts for approximately 10 to 20 percent of cases in Western populations. This makes it a significant but not overwhelming portion of skin-based lymphomas. The condition appears to be less common in Asian countries and in underdeveloped regions of the world, though precise statistics from these areas are harder to come by.[12]
Causes and Origins
The exact cause of primary cutaneous follicle center lymphoma remains unknown to medical researchers. Unlike some other diseases, there is no identified hereditary pattern or genetic predisposition that runs in families. This means that PCFCL is not passed down from parents to children through genes. Instead, it is an acquired disease that develops at some point during a person’s lifetime.[1][3]
What doctors do know is that the disease process begins when normal B cells, which are a type of white blood cell responsible for making antibodies, undergo changes that transform them into cancer cells. These transformed cells no longer function normally to fight infections. Instead, they multiply and accumulate in the skin, forming visible lumps or patches.[1]
Some studies have suggested possible associations between PCFCL and certain infections. Researchers have occasionally found links with bacteria called Borrelia burgdorferi, which causes Lyme disease, as well as with hepatitis C virus and human herpesvirus 8. However, these associations are not consistent enough to be considered definitive causes, and many patients with PCFCL have no history of these infections.[12][13]
The way PCFCL develops is different from follicular lymphoma that starts in lymph nodes rather than skin. This suggests that the skin environment plays a unique role in how this particular type of lymphoma forms and grows.[1]
Risk Factors
Unlike many other cancers, there are no definitive risk factors that have been proven to increase a person’s likelihood of developing primary cutaneous follicle center lymphoma. Researchers have not identified specific behaviors, exposures, or lifestyle factors that clearly raise the risk of this disease.[1]
However, some studies have proposed that certain underlying health conditions might be associated with a higher chance of developing cutaneous B-cell lymphomas in general. These potential risk factors include having an autoimmune disease, in which the immune system mistakenly attacks the body’s own tissues. Type 2 diabetes, a condition affecting how the body processes blood sugar, has also been mentioned as a possible risk factor. Additionally, people who have had other types of cancer in the past may have a somewhat increased risk, though the evidence for all these associations remains preliminary and not conclusive.[3]
The disease affects both men and women and can occur across different age groups, though it is most common in middle-aged and older adults. Being of white ethnicity appears to be associated with higher rates of diagnosis, but this is a demographic observation rather than a modifiable risk factor.[1][4]
Symptoms and Clinical Presentation
Primary cutaneous follicle center lymphoma typically announces itself through visible changes on the skin. The most common presentation is the appearance of one or several firm bumps, raised patches, or tumor-like growths on the skin. These lesions usually develop slowly over time and are generally painless. They do not itch, which distinguishes them from some other skin conditions.[4][12]
The color of these skin lesions can vary. They may appear pink, purplish, red-brown, violaceous, or even close to normal skin color. The surface of the affected area is typically smooth without scaling or flaking, and the lesions usually do not form open sores or ulcers unless the disease is very advanced.[4][6]
Location is an important feature of PCFCL. The lesions show a strong preference for appearing on certain parts of the body. The most common sites are the head, particularly the scalp and forehead, the neck, the trunk including the back and chest area, and sometimes the shoulders. Less frequently, the condition can appear on the arms or legs. When lesions occur on the scalp, they may be accompanied by hair loss in the affected area and visible small blood vessels called telangiectases.[1][12][13]
About 60 percent of patients develop more than one lesion in a specific area of the body, with the bumps or patches grouped together. However, most patients have their disease limited to one region. Only about 10 to 20 percent of people with PCFCL have lesions scattered across multiple different areas of the body at the time of diagnosis.[4]
A distinctive variant of PCFCL, historically known as Crosti lymphoma or reticulohistiocytoma of the back, presents as plaques and tumors on the back that are surrounded by smaller bumps and flat spots. Another presentation pattern, called the miliary variant, shows numerous small, firm, reddish bumps scattered mainly on the forehead and cheeks.[12]
Prevention Strategies
Because the exact cause of primary cutaneous follicle center lymphoma is not known, there are no proven strategies to prevent the disease from developing. Unlike some cancers that can be prevented through lifestyle changes, vaccinations, or avoiding specific exposures, PCFCL appears to occur without clear preventable risk factors.[1]
Since the disease is not inherited and does not run in families, genetic screening of family members is not recommended or useful. There are also no dietary supplements, medications, or behavioral modifications that have been shown to reduce the risk of developing this type of lymphoma.[1]
What is important is early detection and proper diagnosis when skin changes do occur. People who notice unusual lumps, bumps, or patches on their skin that persist for several weeks should seek medical evaluation. Early and accurate diagnosis can lead to timely treatment and better outcomes, even though the disease itself cannot be prevented.[3]
How the Disease Affects the Body: Pathophysiology
In PCFCL, the normal functioning of B cells becomes disrupted. Healthy B cells develop in the bone marrow and then mature in structures called lymph follicles, found in lymph nodes and other lymphoid tissues. Within these follicles, there is a region called the germinal center where B cells undergo changes that help them better recognize and fight specific infections.[1]
In primary cutaneous follicle center lymphoma, B cells that originate from these germinal centers become abnormal and transform into cancer cells. These malignant cells then migrate to the skin, where they begin to accumulate. Under the microscope, the cancer cells that make up PCFCL include different types. The most common are small cells with indented or cleaved nuclei, called centrocytes. Mixed in with these are usually some larger cells with prominent centers in their nuclei, called centroblasts.[1][4]
When a skin biopsy is examined, doctors can see that the cancer cells form clusters in the deeper layers of the skin, specifically the dermis and sometimes extending into the subcutaneous fat beneath. Characteristically, there is a clear zone of normal skin between the very top layer of skin, called the epidermis, and where the cancer cells begin. This separation is known as a grenz zone.[1]
The pattern of growth can vary. In the follicular pattern, the cancer cells cluster together in groups that resemble the normal follicles found in lymph nodes, though these abnormal follicles are usually poorly formed and lack some normal features. In the diffuse pattern, the cancer cells spread more uniformly through the tissue in sheets rather than distinct clusters. Some cases show both patterns together.[1]
Laboratory tests on the cancer cells show they have specific markers on their surface that identify them as B cells. These include proteins called CD19, CD20, CD79a, CD10, and BCL-6. Importantly, most cases of PCFCL do not strongly express a protein called BCL-2, which helps distinguish it from follicular lymphoma that starts in lymph nodes. The cancer cells also typically have a low rate of division and multiplication, which contributes to the slow-growing nature of the disease.[4][12]
Unlike systemic follicular lymphoma, which frequently has a specific genetic change called the t(14;18) translocation involving the BCL-2 gene, PCFCL usually does not have this genetic alteration. This difference at the molecular level is one reason why PCFCL behaves differently from its systemic counterpart and has a much better prognosis.[1][12]
